Overview

Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine: How standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer. The safety of standard gemcitabine plus cisplatin and any side effects that might be associated with it as compared to a fixed dose rate of gemcitabine plus cisplatin.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Gemcitabine